
Keywords: Type 2 diabetes mellitus; Antidiabetic drugs; Cardiovascular safety; Cardiovascular disease; Cardiovascular outcome trials; A1C; glycated A1c hemoglobin; ACEi; angiotensin converting enzyme inhibitor; ACS; acute coronary syndrome; AHA; American heart asso